Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2751-2762

  Gridling, Manuela ^a   Ficarro, Scott B ^b,c   Breitwieser, Florian P ^a   Song, Lanxi ^d   Parapatics, Katja ^a   Colinge, Jacques ^a   Haura, Eric B ^d   Marto, Jarrod A ^b,c   Superti Furga, Giulio ^a   Bennett, Keiryn L ^a   Rix, Uwe ^a,d  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DASATINIB; EPHRIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTEGRIN; INTEGRIN LINKED KINASE; K RAS PROTEIN; LIMS1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOSERINE; PROTEIN; PROTEIN TYROSINE KINASE; RSU1 PROTEIN; SUNITINIB; TBK1 PROTEIN; THREONINE; TYROSINE; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CANCER TISSUE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MASS SPECTROMETRY; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; DRUG SCREENING; ENZYMOLOGY; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918830136     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0152     Document Type: Article

References (50)

1. Lovly CM, Carbone DP. Lung cancer in 2010: one size does not fit all. Nat Rev Clin Oncol 2011;8:68-70.
2. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012;18:349-51.
3. Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009;39:1098-109.
4. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010;6:291-9.
5. Winter GE, Rix U, Carlson SM, Gleixner KV, Grebien F, Gridling M, et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol 2012;8:905-12.
6. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
7. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78-89.
8. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1387-94.
9. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
10. Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer 2010;68:309-18.
11. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-speci fic bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010; 16:483-9.
12. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
13. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
14. Borgdorff V, Rix U, Winter GE, Gridling M, Muller AC, Breitwieser FP, et al. A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene 2014;33:2531-9.
15. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63.
16. Fernbach NV, Planyavsky M, Muller A, Breitwieser FP, Colinge J, Rix U, et al. Acid elution and one-dimensional shotgun analysis on an Orbitrap mass spectrometer: an application to drug affinity chromatography. J Proteome Res 2009;8:4753-65.
17. Bennett KL, Funk M, Tschernutter M, Breitwieser FP, Planyavsky M, Ubaida Mohien C, et al. Proteomic analysis of human cataract aqueous humour: comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ(R)-labelled specimens. J Proteomics 2011;74:151-66.
18. Rix U, Colinge J, Blatt K, Gridling M, Remsing Rix LL, Parapatics K, et al. A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. PLoS ONE 2013;8:e77155.
19. Zhang Y, Wen Z, Washburn MP, Florens L. Re finements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. Anal Chem 2010;82:2272-81.
20. Breitwieser FP, Muller A, Dayon L, Kocher T, Hainard A, Pichler P, et al. General statistical modeling of data from protein relative expression isobaric tags. J Proteome Res 2011;10:2758-66.
21. Ficarro SB, Adelmant G, Tomar MN, Zhang Y, Cheng VJ, Marto JA. Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. Anal Chem 2009;81:4566-75.
22. Parikh JR, Askenazi M, Ficarro SB, Cashorali T, Webber JT, Blank NC, et al. Multiplierz: an extensible API based desktop environment for proteomics data analysis. BMC Bioinformatics 2009;10:364.
23. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1046-51.
24. Reynolds C, Spira AI, Gluck L, Mueller SE, Zhan F, Boehm KA, et al. Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial. Invest New Drugs 2013;31:1330-8.
25. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6.
26. Gao J, Ade AS, Tarcea VG, Weymouth TE, Mirel BR, Jagadish HV, et al. Integrating and annotating the interactome using the MiMI plugin for cytoscape. Bioinformatics 2009;25:137-8.
27. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
28. Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006;7:20-31.
29. Chariot A, Leonardi A, Muller J, Bonif M, Brown K, Siebenlist U. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases. J Biol Chem 2002;277:37029-36.
30. Goncalves A, Burckstummer T, Dixit E, Scheicher R, Gorna MW, Karayel E, et al. Functional dissection of the TBK1 molecular network. PLoS ONE 2011;6:e23971.
31. Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 1999;18:6694-704.
32. Davies SP, Hawley SA, Woods A, Carling D, Haystead TA, Hardie DG. Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. Eur J Biochem 1994; 223:351-7.
33. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-44.
34. Brehmer D, Godl K, Zech B, Wissing J, Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics 2004;3:490-500.
35. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012;2:257-69.
36. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007;104:13283-8.
37. Kim MS, Pinto SM, Getnet F, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature 2014;509:575-81.
38. Ehnman M, Missiaglia E, Folestad E, Selfe J, Strell C, Thway K, et al. Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 2013;73:2139-49.
39. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008;5:e19.
40. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 2012;11:M111.
41. van den Bemd GJ, Krijgsveld J, Luider TM, van Rijswijk AL, Demmers JA, Jenster G. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol Cell Proteomics 2006;5:1830-9.
42. Hafizi S, Ibraimi F, Dahlback B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J 2005;19:971-3.
43. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
44. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1039-45.
45. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009;5:616-24.
46. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477-85.
47. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
48. Augustin A, Lamerz J, Meistermann H, Golling S, Scheiblich S, Hermann JC, et al. Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines. Mol Cancer Ther 2013;12:520-9.
49. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
50. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7.